MolecularMatch and Liquid Biotech USA Partner on Cancer Diagnostics

NEW YORK (GenomeWeb) – MolecularMatch and Liquid Biotech USA plan to partner to develop liquid biopsy technology for cancer, the companies said today.

As part of the partnership, Liquid Biotech, which is developing proprietary circulating tumor cell detection technology, will use MolecularMatch's database to correlate genomic test results with treatments. MolecularMatch, which was founded in 2014, has developed software to match the genetic profile of cancer patients' tumors to clinical trials and available drugs.

MoelcularMatch CEO Kevin Coker said in a statement that the partnership would help bridge the gap between liquid biopsy testing and the "resource-consuming matter of tracking innumerable treatments and trial data."

Liquid Biotech Chairman and CEO Phillip Sass added in the statement that the main advantage of his firm's test is in "early, precision detection," and that MolecularMatch's technology would complement its test by matching the results to available treatment and clinical trials, adding speed.

Liquid Biotech spun out of the University of Pennsylvania and raised $2 million last December to further develop its proprietary circulating tumor cell identification and isolation technology.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Sponsored by

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.